Empowering innovative science and transformativetherapeutics

We are a leading life sciences investor financing highly innovative companies worldwide.

We provide biotech ventures with the resources to develop novel therapies for indications with high unmet medical needs.

We invest in companies that will have a positive impact on patients and society.



Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology


A diverse and
experienced team
driving the future
of health

The scientific, financial and entrepreneurial
expertise of our international team has proven
instrumental to the development of many thriving
biotech ventures.

We are united by our commitment to achieving
success for new, promising companies.


    Global outlook
    Proven performance


    Assets under




    Products brought
    to market


    Products at
    clinical stage


    Backing the
    of tomorrow

    Our portfolio features an exciting mix of biotech
    companies located across Europe and the United
    States, all of which have a high potential to make
    a meaningful impact.


    Dutch med-tech innovator Xeltis lands €15 million European financing from EIB

    Xeltis will use the funding to accelerate the clinical programmes of three restorative devices that can substantially impact cardiovascular

    Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology

    Purchase price includes an upfront payment of EUR 205 million, precommercial milestones for up to EUR 170 million and progressive commercial milestones.

    Kala Pharmaceuticals Acquires Combangio, Expanding its Pipeline with a Clinical-Stage Novel Biologic for the Treatment of Persistent Corneal Epithelial Defect (PCED) and other Rare Ocular Surface Diseases

    Today’s acquisition marks a pivotal moment for Kala and a meaningful acceleration toward our goal of strengthening Kala’s pipeline for the treatment of front and back of the eye diseases,

    Aura Biosciences Presents Final Phase 1b/2 Data for its first Virus-Like Drug Conjugate, AU-011, in Patients with Choroidal Melanoma at the American Academy of Ophthalmology 2021 Annual Meeting

    AU-011 may offer patients a safe, effective first-line therapy for early-stage disease that preserves vision.

    AM-Pharma Appoints Alexander Bastian as Vice President Value & Market Access

    His responsibilities include ensuring broad patient access to ilofotase alfa, AM-Pharma’s drug candidate for the treatment of sepsis-associated acute kidney injury, currently in Phase III clinical development.